Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 2,686 | 2,749 | 3,156 | 3,306 | 3,575 | 3,676 | 4,046 | 4,530 |
| Operating profit | €m | 746 | 1,219 | ||||||
| Net profit | €m | 548 | 647 | 649 | 644 | 346 | 445 | 513 | 1,258 |
| EPS reported | € | 5.32 | 6.18 | ||||||
| Operating cashflow per share | € | 13.62 | 15.78 | ||||||
| Capex per share | € | 1.26 | 0.95 | ||||||
| FCF per share | € | 12.36 | 14.83 | ||||||
| Free cash flow | €m | 1,033 | 1,226 | ||||||
| Net debt | €m | -773 | -1,007 | ||||||
| Book value equity | €m | 4,336 | 4,711 | ||||||
| Book value per share | € | 51.89 | 56.79 | ||||||
| Number of shares | m | 83.55 | 82.94 | ||||||
| DPS (TTM paid) | € | 1.60 | 1.60 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 22.37 | - | ||||||
| P/B LTM | x | 2.29 | 2.45 | ||||||
| P/S LTM | x | 2.70 | 2.85 | ||||||
| P/FCF LTM | x | 9.62 | 9.41 | ||||||
| EV/EBITDA LTM | x | 8.42 | 7.08 | ||||||
| EV/Sales LTM | x | 2.53 | 2.60 | ||||||
| Earnings Yield LTM | % | 4.47% | 4.44% | ||||||
| FCF Yield | % | 10.39% | 10.63% | ||||||
| Quality | |||||||||
| ROE | % | 10.25% | 11.33% | ||||||
| ROIC | % | 10.37% | 14.87% | ||||||
| Operating margin | % | 20.30% | 30.13% | ||||||
| Gross margin | % | 70.58% | 67.52% | ||||||
| FCF/Sales | % | 28.10% | 30.31% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +28.19% | +15.08% | ||||||
| Sales Growth YoY | % | +2.84% | +11.09% | ||||||
| Net Income Growth YoY | % | +28.51% | +14.45% | ||||||
| FCF Growth | % | +676.77% | +51.93% | ||||||
| Operating Profit Growth | % | +50.25% | +48.78% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.17% | 1.15% | ||||||
| Dividend Growth | % | +14.29% | +14.29% | ||||||
| Payout Ratio | % | 26.14% | 26.14% | ||||||
| FCF/Debt | x | 1.19 | 1.27 | ||||||
| Net Debt/EBITDA | x | -0.60 | -0.68 | ||||||
| EBIT/Net interest | x | 20.67 | 29.52 | ||||||
| Net debt/market cap | % | -7.78% | -8.73% | ||||||
| Net debt/Equity | x | -0.18 | -0.21 | ||||||
| Gross debt/equity | x | 0.20 | 0.20 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free